2024-12-23 23:55:42
Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study
Corporate/ 2023-07-23
Bimekizumab Demonstrated Long-Term Maint...

- 80 to 100% of BE ABLE 1 responders maintained a response of at least 90% disease improvement (PASI90) over 60 weeks with bimekizumab

Adagene Announces a Platform Evaluation of the Dynamic Precision Library with Celgene Corporation
Health/ 2023-07-22
Adagene Announces a Platform Evaluation ...

SAN FRANCISCO,March 4,2019-- Adagene,Inc.,an innovative antibody discovery and engineering company,today announced a multi-target platform e...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release